- Litigation Finance Insider
- Group Class Action: An Emerging Legal Risk for Pharma Businesses
Group Class Action: An Emerging Legal Risk for Pharma Businesses
Michael Frisby of Stevens & Bolton warns pharma companies that they may soon find themselves the target of a group action given the regulatory attention focused on the pharma sector and the appetite amongst litigation funders to invest in group actions, and cites recent examples where claims alleging breaches of competition law or high profile consumer claims were brought. Read more.